Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospitals Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely. For the new study, researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to a small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper. These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita.

Read the rest here:
Molecules identified that reverse cellular aging process - Daily Times

Bone Marrow Stem Cells Comments Off on Molecules identified that reverse cellular aging process – Daily Times | April 28th, 2020

A Co Armagh cancer survivor is inspiring people to Race for Life at Home and carry on the fight against the disease in these unprecedented times.

Clare Crossey (33), a care worker from Lurgan who was diagnosed with leukaemia in February 2018, had hoped to take part in Cancer Research UK's Race for Life in Belfast on Sunday, May 24.

Unfortunately the Belfast Race for Life is among events which organisers Cancer Research UK have postponed this spring and summer to protect the country's health during the coronavirus outbreak.

But as the nation's lockdown continues, undeterred women and men are already vowing to carry on and complete a Race for Life at Home challenge in their garden or their nearest green space.

Clare is unable to take up the challenge right now, as she is recovering from a bone marrow transplant, but is determined to lend her support and has recruited her sister Alison and daughters Meabh (8) and Lily (11) - who are limbering up with Joe Wicks on YouTube every morning.

The mum-of-two's life changed very suddenly in February 2018 when she was diagnosed with acute myeloid leukaemia, a cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells.

She has faced a tough battle for survival over the past two years and this time last year was in isolation receiving treatment and a stem cell transplant.

As she now faces isolation again to protect herself from coronavirus, Clare is remaining upbeat.

She says: "I now have a brand new immune system, almost like I have been reborn, so I need to have all the injections a new baby has.

"This places me at especially high risk from the coronavirus. It is frightening, but with the help of family, I am being very careful.

"We're all going to be spending a lot of time indoors this spring, so it feels good to take back some control and plan something positive to help me and to help people who are going through cancer right now.

"That's why I am happy to ask people to please join in the fun and still feel part of the Race for Life community."

Clare recalls how her life changed virtually overnight two years ago.

She had just finished night duty as a domiciliary care assistant when she started to feel very tired and unwell.

She then developed a rash on her chest and bruising on her legs.

Concerned, she looked up her symptoms and was alarmed to discover she could have leukaemia and immediately made an appointment with at the local health centre. A doctor felt that she was being over-anxious and she was sent home with details of the Samaritans helpline but within two days she was being told in hospital she was lucky to be alive.

Clare recalls: "I had a feeling in the back of my head that things weren't right.

"The doctor obviously did not agree with my suspicions as they gave me the number for the Samaritans, a prescription for beta blockers and told me to make an appointment for the following Tuesday for blood tests. This was on a Friday and Tuesday seemed so far away.

"As I left the surgery in tears, my younger daughter Meabh's school called me to say she had fallen and hit her head. That was the last thing I needed, but thankfully she was okay.

"I described my symptoms to my boss and we thought perhaps I just needed a week off work as I was over-tired.

"My mother was helping with the girls, who were just five and nine at the time, and she was completely dumbfounded to find me having a bath at 2.30am on the Saturday morning. I had thought perhaps the heat would help with the pains I was having."

After her bath Clare did fall asleep but was stunned when she woke to discover she had lost a whole day, sleeping for 24 hours straight.

She was further alarmed on waking to discover she had blood round her mouth as her gums were bleeding and she also found a huge bruise on her thigh, which was swollen.

She rang Craigavon hospital and was advised to come to A&E where blood tests were taken.

She recalls: "A short time after arriving at the hospital I was called to the yellow area and I knew from my job that was the admissions area. My bloods came back very quickly and when both a doctor and nurse came to talk to me, I just knew it was serious."

Clare was advised to go to the City Hospital right away and on arrival was met by a consultant and nurse who admitted her immediately and broke the news that she might have leukaemia.

Clare recalls: "I cried and the first stupid question I asked was, 'Am I going to lose my hair?' My thinking was that if I lost my hair the girls would know I was really ill, so I would have to tell them the truth."

Chemotherapy treatment started immediately and Clare was told that had she waited until the following Tuesday for blood tests, she may not have been alive. The cancer was 85% through her body and she was given around 16 hours to live.

She was offered a place on a Cancer Research UK trial called AML 19, which involved 10 days of chemo, day and night, from February 4 until the end of March.

She says: "I was in hospital for six to eight weeks at a time and sometimes didn't even see the kids. That was really difficult as they were so young, but my parents Margaret and Pat were a great help."

From February to September 2018, Clare had intense chemotherapy and tests showed her bone marrow was clear.

However, there was another blow in December when further tests revealed the leukaemia was back.

"I was devastated," said Clare. "I was readmitted to hospital on January 5 last year and remained there until March 7. I was allowed out for my daughter Lily's confirmation and we had a party before I went back into hospital that night."

Clare was forced to remain in quarantine in a stem cell room while receiving full body radiation and chemotherapy injections.

She needed a stem cell transplant to save her life. Her brother Darren and sister Alison - both musicians living in America at the time - had already been tested for stem cell transplant and Alison was relieved to be a 100% match.

On April 15 of last year, Clare went through her stem cell transplant.

Two weeks later she suffered a severe reaction and her body went into toxic shock.

She recalls: "I was told it was rare to have side effects but I had them all.

"My oesophagus was burned with the radiation and I couldn't walk or talk.

"I couldn't breathe and began vomiting blood. I woke up with an ICU team at my bedside that had to literally cut my clothes off due to swelling. I apparently had put on 4st in fluid due to the toxic shock. I remember asking, 'Am I going to die?'"

It was at this point an unusual encounter in the hospital changed things. A man visiting another patient with a religious relic from the saint Padre Pio enclosed in a frame asked if he could leave it with Clare, believing it might be something that would give her strength.

She decided that if she was to survive she had to be positive.

She says: "That was on May 2 and as I held the frame I was in tears, but next morning I got up and began physio, although I wasn't able to wear either shoes or slippers after gaining 4st in fluid due to toxic shock.

"I started to eat shortly after and nobody could believe it. I was discharged on May 15."

Today she feels indebted to her family and the staff at 10 North in Belfast City Hospital for their amazing care.

"I would also like to say a special thank-you to all my cousins and close friends for their love and support throughout my journey," she says. "My sister flew home from the US to be with me for the second round of treatment but my close friends, cousins and aunt Bernadette were with me the whole time."

And after everything she has been through, she is hoping to give something back by calling on people to support Cancer Research UK's Race for Life at Home event.

Last year Race for Life participants in Northern Ireland raised 98,646 to support vital research to develop gentler and more effective treatments for cancer.

Many of the scientists and researchers funded by Cancer Research UK are currently being redeployed to help in the fight against Covid-19, including assisting with testing.

By helping to beat coronavirus, the charity can lessen the impact it is having on the care of cancer patients.

Jean Walsh, Cancer Research UK's spokesperson for Northern Ireland, said: "At a time when it feels like everything is at a standstill, there is one thing that hasn't stopped - cancer.

"Our priority as a charity is ensuring that people affected by cancer are getting the support they need right now.

"But we are already getting people asking about doing Race for Life at Home because they don't want to see the charity lose out on vital funding. It's truly humbling to see the response.

"So, from their homes, we'd love for supporters to join us and Race for Life at Home in these challenging times. From a run or 5K walk around the garden to limbo in the living room, there is no wrong way to Race for Life at Home.

"With no entry fee, people might choose to twerk, limbo, star jump, squat, skip, dance, or come up with their own novel way of taking part and share it with friends. The message is very much that 'while we might be apart, we're doing this together'. There is no wrong way to get involved and join our community."

You can visit raceforlife.org and sign up free for ideas on how to create your own Race for Life at Home challenge.

And the Cancer Research UK Race for Life Facebook page will help people feel energised with weekly live workout sessions.

Organisers are also inviting participants to join the Race for Life at Home community by sharing photos and videos on social media using the hashtag #RaceForLifeAtHome.

Cancer Research UK was able to spend over 2m last year in Belfast on some of the UK's leading scientific and clinical research.

A new date for Race for Life Belfast has been set for Wednesday, October 7.

Participants who have already signed up for a Race for Life event which is now postponed will be contacted directly by the charity. Participants will be transferred to the new date but if they can't make it there is the option to request a refund or donate the entry fee to help fund cancer research.

Visit raceforlife.org or call 0300 123 0770. Join in and share with #RaceForLifeAtHome

Belfast Telegraph

Read more:
Co Armagh mum diagnosed with leukaemia and told that she had just 16 hours to live now inspiring people to sign up and do the Race for Life at Home in...

Bone Marrow Stem Cells Comments Off on Co Armagh mum diagnosed with leukaemia and told that she had just 16 hours to live now inspiring people to sign up and do the Race for Life at Home in… | April 28th, 2020

GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

MarketInsightsReports has announced the addition of the Global Stem Cell Therapy Market Research Report 2020 The report focuses on global major leading players with information such as company profiles, product picture and specification.

Get Sample Copy of Stem Cell Therapy Market Report

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?Mode=10

Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), request free sample for complete list of companies.

The leading players of industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Stem Cell Therapy Market Segmentation by types, Applications and regions:

Market Segment by Type covers:

Autologous

Allogeneic

Market Segmented by Applications:

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Market Segment by Regions:

North America (the United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)

Available [emailprotected] (Exclusive new year offer Flat 20%- Use code MIR 20):

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/discount?Mode=10

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about global market:

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Note:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Visit complete report@

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=10

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More here:
Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) - Jewish Life News

Bone Marrow Stem Cells Comments Off on Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) – Jewish Life News | April 28th, 2020

Naina Mishra

Tribune News Service

Chandigarh, April 28

Fifty per cent Covid-19 cases in the city are from two affected pockets Bapu Dham Colony and Sector 30-B.

Though the street lanes from where cases are being reported are being sealed in Sector 30-B, residents have reportedly been found violating the social distancing norms by crossing roofs or playing indoor games in gatherings. This has now prompted the UT Administration to install CCTV cameras to keep a vigil on the residents in these pockets.

A total of 16 cases have been reported from Bapu Dham Colony and 14 from Sector 30-B. Manoj Parida, UT Adviser, said the outbreak needed to be contained by focusing resources at Bapu Dham Colony in Sector 26 and Sector 30-B.

CCTV cameras will be installed and drones will be used to nail those violating the norms. The police will also patrol the area regularly by donning personal protective equipment, said Parida.

MC Joint Commissioner Anil Garg said: Residents are not following social distancing and curfew orders.

Devinder Singh Babla, councillor, said: We have prepared a team of volunteers in Sector 30 and we are sealing the areas ourselves. Those found violating the norms will be penalised.

Read the original:
Give child a healthy life, not thalassaemia - The Tribune

Bone Marrow Stem Cells Comments Off on Give child a healthy life, not thalassaemia – The Tribune | April 28th, 2020

Even in times of the COVID-19 crisis, life-saving blood stem cells are brought to patients - by committed people like Maria

Originally published by DKMS

Maria Schmiing is a DKMS employee and has also been a volunteer stem cell courier for about two years. A few days ago, she took a transplant from Germany to the US - a particularly difficult challenge in times of the COVID-19 crisis. Currently, entry to the US is only possible because DKMS, with the support of the US Stem Cell Donor Register: National Marrow Donor Program (NMDP/Be the Match), has obtained a special permit for stem cell couriers to enter the country - so that patients can receive urgently needed transplants.

"It was through an acquaintance of mine that I became aware of it several years ago. She is a teacher and carries out stem cell transports during the school holidays - I was immediately enthusiastic about it and signed up for it," says Maria Schmiing from Cologne. She applied to Ontime Onboard Courier GmbH, one of the transport companies that DKMS works with to bring life-saving blood stem cells to the recipients.

Maria's first assignment took her to Leiden in the Netherlands - an important place in the fight against blood cancer, as the World Marrow Donor Association (WMDA) has its headquarters there. "I was really excited before I even started the journey," she recalls.

Afterwards many further assignments followed, and it was because of this job as a courier that her desire to work at DKMS was born. "For me, the circle is complete; I'm doing something meaningful with my life. I am very aware of what I am doing this for: for the patients who need our help. What I think is great is that I am also really supported by my team and my managers, especially in the current situation."

Blood stem cell couriers like Maria Schmiing are currently in great demand to ensure that blood stem cell donations reach their recipients all over the world safely, even during the COVID-19 crisis. A few days ago the latest task for the 34-year-old was to travel to the US. "The procedure for a courier mission is actually always the same," she explains, "During the briefing the day before, we go through all documents together and the entire itinerary is discussed. Everything important detail is marked and addressed." But something is different at the moment: the couriers must carry a special permit that allows them to enter the US. "This must be presented upon entry and exit."

The next stop for Maria was the collection centre the next morning. There she received the life-saving blood stem cells from specially trained staff. These had previously been collected from a DKMS donor and prepared for transport. All documents and data were double checked based on the 4 eye principle before the transplant was handed over. "We especially look at the donor number and compare it, because we have to make sure that the patient receives the right transplant".

Afterwards Maria could start her journey. Stem cell couriers are allowed one additional piece of hand luggage only to be able to stay flexible on the way. "Most important are the blood stem cells or the bone marrow. We must not lose sight of the transplant during the entire journey. I look after this suitcase like my own personal treasure, like a mother who looks after her children. I am aware of the responsibility I carry and this stays with me until I have delivered the blood stem cells safely to the patient's clinic."

Before the departure to the US, she made sure that at the Frankfurt Airport the suitcase with the stem cells was not X-rayed. "I always explain that this is harmful to the transplant something most people know. Only after an officer has brought the suitcase through the security area, do I then follow. This is the only time we hand the suitcase over to somebody else. Fortunately, there were no problems either at the security check or at customs.

Once on the plane she informed the crew - an important and regular task for her - and did not let the suitcase out of her sight during the flight. "Sleep, of course, is out of the question. We are not allowed to drink alcohol 24 hours before and during the flight and we of course have to take the suitcase everywhere with us."

Upon arrival in the US, Maria noticed two differences "After landing, several security officers entered the plane and talked to the crew - only then were we allowed to disembark. In addition to this, they took the temperature of all passengers.

She then continued her journey by taxi to the transplant clinic. "Everything went really well, and I was met at the clinic by a member of staff. Again there, we double checked everything and went through the documents according to the four eye principle. Once we get back to Germany, there is also a debriefing and I then return the suitcase."

After handing a transplant over, there is always a moment of great relief for Maria: "The tension disappears. Afterwards she has a ritual, which is very important for her. "I go to the hotel, have a shower and then go out and raise a glass of beer for the patient. I think about how they are doing and what is still ahead of them. I then tell myself that from my side I've done everything I can to help them and I wish them all the best."

Going out and having a beer was not possible this time, as neither shops nor bars were open in the American city - even the hotel restaurant was closed. "I changed my ritual and toasted the unknown patient with a glass of tap water in my room!"

The next day she went back to Germany and soon the next flight will be scheduled for her - couriers are rare in this COVID-19crisis-ridden time. "My learning from this journey: I will take an emergency ration of trail mix with me, you never know," she says with a wink. She reflects on her commitment to patients. "I am still available when my help is needed. I am aware of the risk and take the best possible care and comply with all safety precautions. It is also clear that patients cannot wait - and despite everything with the current situation they should still be given a chance at life.

Learn more about how you can help deleteblood cancer atDKMS.org

More here:
On the Road As a Stem Cell Courier Press Releases on CSRwire.com - CSRwire.com

Bone Marrow Stem Cells Comments Off on On the Road As a Stem Cell Courier Press Releases on CSRwire.com – CSRwire.com | April 27th, 2020

Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the Harvard University team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospital's Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely.

For the new study, Harvard researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper.

These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita. These compounds boosted TERC levels in those stem cells and restored telomeres to their normal length. However, rather than a scattergun approach, the team really wanted to test for safety and see if the treatment could precisely target stem cells carrying the right ingredients for telomerase formation.

More specifically, the team wanted to see if this could be achieved by having the PAPD5-inhibiting drugs recognize and respond to another important component of telomerase, a molecule called TERT. To do so, in the next round of experiments the team used human blood stem cells and triggered mutations in the PARN gene that give rise to dyskeratosis congenita. These were then implanted into mice that were treated with the compounds, with the team finding the treatment boosted TERC, restored telomere length in the stem cells and had no ill effects on the rodents.

This provided the hope that this could become a clinical treatment, says Nagpal.

The team will now continue its work in an effort to prove these small molecules are a safe and effective way to apply the brakes to dyskeratosis congenita, other diseases, and possibly aging more broadly.

We envision these to be a new class of oral medicines that target stem cells throughout the body, Agarwal says. We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.

The research was published in the journal Cell Stem Cell.

Source: Boston Childrens Hospital via Harvard University

View post:
Molecules identified that reverse cellular aging process - New Atlas

Bone Marrow Stem Cells Comments Off on Molecules identified that reverse cellular aging process – New Atlas | April 27th, 2020

Capping decades of research, a new study may offer a breakthrough in treatingdyskeratosis congenitaand other so-called telomere diseases, in which cells age prematurely.

Using cells donated by patients with the disease, researchers at theDana-Farber/Boston Childrens Cancer and Blood Disorders Centeridentified several small molecules that appear to reverse this cellular aging process.Suneet Agarwal, the studys senior investigator, hopes at least one of these compounds will advance toward clinical trials. Findings werepublished Tuesday in the journal Cell Stem Cell.

If so, it could be the first treatment for dyskeratosis congenita, or DC, that could reverse all of the diseases varying effects on the body. The current treatment, bone marrow transplant, is high-risk, and only helps restore the blood system, whereas DC affects multiple organs.

The compounds identified in the study restore telomeres, protective caps on the tips of our chromosomes that regulate how our cells age. Telomeres consist of repeating sequences of DNA that get shorter each time a cell divides.

The bodys stem cells, which retain their youthful qualities, normally make an enzyme called telomerase that builds telomeres back up again. But when telomeres cant be maintained, tissues age before their time. A spectrum of diseases can result not just DC, but also aplastic anemia, liver cirrhosis, and pulmonary fibrosis.

The discovery of telomerase 35 years ago, earninga Nobel Prize in 2009, galvanized the scientific world. Subsequent studies suggested the enzyme could be a key to reversing aging, as well as treating cancer, in which malignant cells become immortal and divide indefinitely.

For years, researchers have tried to find a simple and safe way to manipulate telomerase, preserve telomeres, and create cures for telomere diseases.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Agarwal, who has researched the biology of telomerase for the past decade. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

DC can be caused by mutations in any of multiple genes. Most of these mutations disrupt telomerase formation or function in particular, by disrupting two molecules called TERT and TERC that join together to form telomerase. TERT is an enzyme made in stem cells, and TERC is a so-called non-coding RNA that acts as a template to create telomeres repeating DNA sequences. Both TERT and TERC are affected by a web of other genes that tune telomerases action.

One of these genes is PARN. In 2015, Agarwal and colleagues showed inNatureGeneticsthat PARN is important for processing and stabilizing TERC. Mutations in PARN mean less TERC, less telomerase, and prematurely shortened telomeres.

Thenew study, led by Harvard Medical School postdoctoral fellow Neha Nagpal, delved further, focusing on an enzyme that opposes PARN and destabilizes TERC, called PAPD5.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Nagpal, first author on the paper.

Nagpal and her colleagues first conducted large-scale screening studies to identify PAPD5 inhibitors, testing more than 100,000 known chemicals. They got 480 initial hits, which they ultimately narrowed to a small handful.

They then tested the inhibitors in stem cells made from the Martins cells and those of other patients with DC. To the teams delight, the compounds boosted TERC levels in the cells and restored telomeres to their normal length.

But the real challenge was to see if the treatment would be safe and specific, affecting only the stem cells bearing TERT. To test this, the team introduced DC-causing PARN mutations into human blood stem cells, transplanted those cells into mice, then treated the mice with oral PAPD5 inhibitors. The compounds boosted TERC and restored telomere length in the transplanted stem cells, with no adverse effect on the mice or on the ability to form different kinds of blood cells.

This provided the hope that this could become a clinical treatment, says Nagpal.

In the future, Agarwal, Nagpal, and colleagues hope to validate PAPD5 inhibition for other diseases involving faulty maintenance of telomeres and perhaps even aging itself. They are most excited about two compounds, known as BCH001 and RG7834 that are under further development.

We envision these to be a new class of oral medicines that target stem cells throughout the body, Agarwal says. We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.

One email, each morning, with our latest posts. From medical research to space news. Environment to energy. Technology to physics.

Thank you for subscribing.

Something went wrong.

See the original post:
Breakthrough to halt premature aging of cells - ScienceBlog.com

Bone Marrow Stem Cells Comments Off on Breakthrough to halt premature aging of cells – ScienceBlog.com | April 27th, 2020

Doctors are hoping stem cell therapy could be a weapon in the fight against coronavirus. On Friday, regenerative medicine company Mesoblast announced a 300-person trial to determine whether stem cell treatments will work in COVID-19 patients suffering from severe lung inflammation.

One hospital in New York tried it as an experiment with 12 patients, 10 of whom were able to come off of ventilators.

"What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better," Dr. Karen Osman, who led the team at Mount Sinai, told CBS News' Adriana Diaz.

The doctor said she was encouraged by the results, though she was hesitant to link the stem cell procedure to her patients' recovery.

"We don't know" if the 10 people removed from ventilators would not have gotten had they not gotten the stem cells, she said. "And we would never dare to claim that it was related to the cells."

She explained that only a "randomized controlled trial" would be the only way "to make a true comparison."

Luis Naranjo, a 60-year-old COVID-19 survivor, was one of Mount Sinai's stem cell trial success stories. He told Diaz in Spanish that he was feeling "much better."

Naranjo's daughter, Paola, brought him to the emergency room, fearful she would not see her father again. Like so many families struck by the coronavirus, she was not allowed inside with him.

"I forgot to tell him that I love him," she said. "All I said was go inside, I hope you feel better."

During his hospital stay, Naranjo was unconscious and on a ventilator for 14 days.

Doctors proposed giving him stem cells from bone marrow in hopes it would suppress the severe lung inflammation caused by the virus.

Now, Naranjo credits the doctors who treated him for his survival. Though income from his family's jewelry business has been cut off and they found themselves falling behind on rent, Naranjo said he is focused primarily on his recovery and regaining the 25 pounds he lost at the hospital.

Although stem cell treatment, usually reserved for other diseases like rheumatoid arthritis, might end up being another step toward helping coronavirus patients recover, Dr. Osman was quick to say it would not be a "miracle treatment."

"The miracle treatment will be a vaccine," she said.

Excerpt from:
Doctors experiment with stem cell therapy on COVID-19 patients - KTVQ Billings News

Bone Marrow Stem Cells Comments Off on Doctors experiment with stem cell therapy on COVID-19 patients – KTVQ Billings News | April 25th, 2020

In some patients, COVID-19 has triggered a cytokine storm, an immune system response in which the body attacks its own cells. Jung painted a picture of a boxing match in which "fighter" immune cells are being called upon to battle the virus. This battle generates lots of fluid, waste and pus, making it difficult for the alveoli to pick up the oxygen a person breathes in, leading to multi-organ failure.

"These immune cells, neutrophils and other fighter immune cells, are like that. They don't care if it's a virus or our own cells. If you're infected, they're all enemies," Jung said. "So what they're going to do is they're going to start to kill everybody, basically."

Why exactly some people's immune systems go into overdrive, Jung said, is unknown, but he said it can happen to anybody.

"If we are up to the level where we can fight well without going into a coma or anything, then 14 days later, our body can provide an antibody," Jung said. "An antibody will neutralize this virus very quietly."

Strengthening the immune system

Eating certain foods can help keep your immune cells strong. Jung said vegetables, for example, stimulate the circulation of blood cells from bone marrow.

"Those bioactive reagents can support our immune systems by sending them the appropriate amount of stem cells, just in case some tissue cells are damaged and we need to replenish them. For example, if your lung cell has been damaged and they need to be replaced, that could be done by the stem cell that has been moved from the bone marrow and located around the lung area," said Jung, who encourages eating a variety of different colored vegetables.

Read more:
BCU biology professor offers tips to prevent COVID-19 infection - Sioux City Journal

Bone Marrow Stem Cells Comments Off on BCU biology professor offers tips to prevent COVID-19 infection – Sioux City Journal | April 25th, 2020

Wed, Apr 22, 2020 - 5:50 AM

PATIENTS from around the world have benefited from Parkway Cancer Centre's (PCC) comprehensive and holistic approach to treating haematological cancers, or cancers of the blood. The field of haematology covers a broad spectrum of blood disorders, with the World Health Organization estimating that there are as many as 72 types and sub-types of this form of cancer.

With one of the largest and most experienced teams of haematologists in Singapore - comprising three oncologists and one paediatric oncologist - PCC is able to offer specialised care for the management of a wide range of adult and childhood conditions, including leukaemia and lymphoma, among many others.

Significantly, this core group of haematologists is supported by dedicated transplant physicians, oncology and transplant nurses, transplant coordinators, counsellors and allied health professionals. The breadth of its resources allows PCC to adopt a holistic approach to care that enhances the patient journey and results in better healthcare outcomes.

Treatments provided by the haematology oncology team range from intensive chemotherapy, molecular targeted therapy and novel immunotherapy to stem cell transplantation. For each patient, the team devises a personalised treatment plan that aims to optimise clinical outcomes.

"In all diseases, especially cancers, it is important to be able to see patients as individuals in need of treatment that extends beyond specialised investigations and medications. This is best achieved by a multidisciplinary team approach that identifies the patient's medical and emotional needs, preferences and values," said Dr Colin Phipps Diong, Senior Consultant, Haematology Oncology at PCC.

"We are able to draw on the collective expertise of our multidisciplinary team and use our knowledge bank of experience gleaned from successfully treating some of the most challenging and complex cases. Being at the fore of medical advancements gives us the capability and confidence to provide our patients with current treatment options," he added.

A Pioneer in Bone Marrow Transplantation

Reflecting the depth of its expertise in this specialised field, PCC is the only private healthcare provider that offers a comprehensive adult and paediatric blood and bone marrow transplant programme. Indeed, the centre's haematology team performed the first bone marrow transplant in a private hospital setting in Singapore more than two decades ago.

Bone marrow transplantation, known formally as haematopoietic stem cell transplantation, is a specialised procedure which has proven to be effective in treating many types of cancers, as well as blood and autoimmune disorders such as leukaemia and lymphoma.

Since the 1950s, more than one million transplants have been performed globally, with the success of the procedure largely dependent on the skill and experience of the multidisciplinary transplant team. Transplant specialists at the PCC Haematology and Stem Cell Transplant Centre perform transplants from family members, unrelated donors, and cord blood, for a range of conditions, both non-malignant (thalassaemia, aplastic anaemia) and malignant (acute leukaemias, lymphoma, myeloma).

These specialists have extensive experience in bone marrow transplants in both adult and paediatric patients, having trained and worked at some of the leading transplant centres around the world.

Even though stem cell transplantation has been proven to save lives, there are still risks associated with the procedure. At PCC, these risks are clearly explained to the patients and caregivers before they consent to the procedure. "Complex treatment decisions are regularly discussed between the transplant physicians to formulate an optimal plan for our patients," explained Dr Diong.

The transplantation process involves several important stages: Conditioning where the patient receives chemotherapy and/or radiation to kill the diseased cells and to change the immune system; infusion of healthy stem cells into the body to replace the damaged cells; engraftment, when the transplanted stem cells begin to grow and produce healthy red and white blood cells and platelets over the course of two to four weeks; and post-transplant recovery where the "new" immune system matures and develops the ability to fight infections and blood cancer cells.

Looking ahead, PCC will continue to develop its expertise and services to stay ahead of the curve in treating haematological cancers. "We are always looking ahead. It is important that we build our team further to broaden our regional footprint and expand services to bring our patients access to cutting-edge science like CAR T-cell therapies," said Dr Diong.

"In this regard, we strive to develop services, infrastructure, and facilities that are internationally accredited together with our partners in Parkway. At the same time we will continue to work with all stakeholders to ensure that cost is manageable and more patients have access to our transplant services."

PCC's holistic philosophy

See the article here:
A leader in treating haematological cancers - The Business Times

Bone Marrow Stem Cells Comments Off on A leader in treating haematological cancers – The Business Times | April 25th, 2020

A few weeks afterreceiving chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, many patientsexperience prolonged reductions in blood cell counts, possibly making them morevulnerable to infections.

Two recent studies characterized the extent and duration of postCAR-T cytopenia among patients receiving CAR-T therapy for hematological malignancies with 1 study offering insights on some of the possible factors that may influence hematological count recovery.

Whats important to know is that by day 90, mostpatients recover, noted UroosaIbrahim, MD, stemcell transplantation and cellular therapy fellow at the Tisch Cancer Instituteof the Icahn School of Medicine at Mount Sinai,New York, who coauthored 1 of the studies. Were supporting them for [approximately]3 months [with treatment], but then theyll recover, which is good to know.

One study by MemorialSloan Kettering Cancer Center (MSKCC) researchers followed 83 adult patientswho received CAR-T therapy: 40 patients received 1 of 2 Food and DrugAdministration (FDA)-approved therapies, axicabtageneciloleucel (axi-cel; Yescarta) ortisagenlecleucel (tisa-cel; Kymriah), to treat relapsed/refractory B-cell lymphoma.

The remainder comprised 37 patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were currently enrolled in a clinical trial in which they received an experimental CAR-T therapy where cells express the 19-28z CAR construct (ClinicalTrials.gov Identifier: NCT01044069), and 6 multiple myeloma patients who received a different experimental CAR-T construct that targets the B-cell maturation antigen (BCMA) (ClinicalTrials.gov Identifier: NCT03070327). The findings were presented at the annual Transplantation and Cellular Therapy Meetings of ASCT and CIBMTR in February 2020.1

By 1 month, theresearchers observed that 24% of patients experienced a complete recovery ofhemoglobin, platelets, absolute neutrophil count, and white blood cell counts recovery being defined as reaching safe levels, and without requiringtransfusions or treatment with growth factors.

Recovery of hemoglobinwas noted in 61% of patients, platelets in 51% of patients, absolute neutrophilcount in 33% of patients, and white blood cell count in 28% of patients.Examining 41 patients at 3 months, those figures were 93%, 90%, 81%, and 59%,respectively, and overall, 56% saw a complete blood count recovery.

The results werebroadly consistent with recent research by Dr Ibrahim and Keren Osman, MD,associate professor and director of medicine at the Icahn School of Medicine atMount Sinai and director of cellular therapy service in the bone marrow andstem cell transplantation program at the schools Tisch Cancer Institute. Thatstudy comprised 50 patients 41 with multiple myeloma and 9 with diffuse largeB-cell lymphoma who received either axicabtagene ciloleucel, or 1 of 2 experimentalanti-BCMA CAR-T therapies, bb2121 or bb21217.

See the original post here:
What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies? - Cancer Therapy Advisor

Bone Marrow Stem Cells Comments Off on What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies? – Cancer Therapy Advisor | April 24th, 2020

Alumni members of National Institute of Technology - Tiruchi (NIT-T) holding key positions in tech companies across the globe have responded overwhelmingly through their knowledge support, innovative devices, fund mobilisation, and production of personal protection equipment for dealing with the COVID-19 pandemic.

An associate of Global Consortium of Cell Therapy Companies, Stempeutics, an Indian stem cell company of which B. N Manohar, an alumnus of ECE 1977 batch is the Chief Executive Officer, will shortly be supplying clinical-grade Mesenchymal Stem Cells (multi-potent stem cells found in the bone marrow used for making and repairing skeletal tissues) to those in need. Manufactured in the Manipal GMP facility under approval of Drug Controller General of India, the multi-potent stem cells have been found to reduce the symptoms of pneumonia induced by COVID-19 and halt its advancement to Acute Respiratory Distress Syndrome, NIT-T Director Mini Shaji Thomas said.

S. K. Ramesh, an alumnus of 1981 batch ECE holding a senior position in California State University, Northridge, is involved along with his colleagues in creation of life saving face shields and other personal protection equipment for donating the same to healthcare workers in hospitals throughout Southern California.

Blooom Energy, founded by K. R. Sridhar, who had completed his mechanical engineering degree from the then Regional Engineering College Tiruchi, and subsequently did his masters degree in Nuclear Engineering, and Ph.D. in Mechanical Engineering from the University of Illinois, Urbana-Champaign, has undertaken the task of repairing ventilators on a bulk scale in partnership with Stanford Health Care.

Chief Innovation Officer at Dulso, United Arab Emirates, Madhumohan Sreeram, an alumnus of NIT-T who had completed B.Tech in Chemical Engineering in 1982, has been in the forefront in carrying out sanitisation of the municipality of Dubai after identifying a suitable disinfectant QUATPLUS TB, which is a Quaternary Ammonium Compound product approved by United States Environmental Protection Agency and American chemistry councils Center Biocide Chemistry (CBC) and has been listed in their recommended EPA pre-approved products for COVID-9 disinfection application.

Richard Sekar, an alumnus who had completed Production Engineering in 1983 leads Warriors Against Virus a team of 371 volunteers in the Bay Area, USA, for stitching facial masks for hospital requirement. IcarusNova, of which Sapna Behar, an alumna (1990, EEE), is the Director and Founder, has partnered with LifeSignals to design a wireless biosensor-based patch, with ISO 13485 accreditation, for early detection and continuous monitoring of COVID-19 symptoms. The patches when affixed on the chest area can monitor the temperature, breathing rate, trace ECG and heart rate as a real time data. The data can be transferred to the users phone through an app. The system reduces the risk of contamination between patients and other individuals.

Admiral Superintendent of Naval Dockyard, Vishakapatnam, Sreekumar Nair (ECE, 1986), has led a team to design an innovative portable multi-feed oxygen manifold using a six-way radial header fitted to a single cylinder. This becomes essential when the existing hospital facilities for critical care management becomes limited and a need arises for catering to multiple patients. Rapid trials have been done at Naval Hospital INHS Kalyani. The entire assembly could be set up within 30 minutes.

Appreciating the efforts of the alumni members, Prof. Mini Shaji Thomas said the various contributions in diverse sectors was a matter of pride.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

See the original post:
Robust response by NIT-T alumni to tackle Covid-19 pandemic - The Hindu

Bone Marrow Stem Cells Comments Off on Robust response by NIT-T alumni to tackle Covid-19 pandemic – The Hindu | April 24th, 2020

- Advertisement -

The benefits of Stem cells therapy vary, some of the benefits of stem cells are because of their potential in the treatment of medical conditions, but it is not the only way they can be utilized. A few of the benefits are as follows: To know what is a Stem Cell Therapy.

Medically, stem cells are used in therapies to treat certain diseases and conditions, many treatments require a transplant of organs and tissues but the organs and tissues are donated and the waiting list for donation is quite long. People stay on the transplant lists for years and many dont live to see their name move up the list or are not viable to receive donor organs or tissues, and in such cases stem cells can provide an effective and faster and better alternative in some diseases. The most popular form of stem cell therapy is the bone marrow transplant, and many others are considered safe in treatments of conditions and diseases like:

There are many other stem cell therapies but not all of them have been approved as safe and effective. But like in the case of a burn victim, the replacement of the burned area with stem cells can be utilized to make new tissues and save the trouble of finding a tissue donor. It is a very painful experience and everything that can be done should be done to lessen the pain and start the healing process quickly for the sake of the patient.

Research done on animals like dogs and horses and cats showed us that this form of research not only advances the development of stem cell therapies and treatments; for the benefit of veterinary medicine, but also resulted to be very beneficial for human treatments as well.

Animals that have diseases that nearly mimic the ones humans have as well are used as ideal models to experiment the development of stem cell therapies in medical conditions that humans and animals both have, like ligament injuries or stroke etc.

Diseases like cancer and conditions like birth defects are quite common these days so, many clinical and experimental trials are popping up to better fight these diseases. Scientists are now looking for ways that they can use to come up with stem cell treatments to better develop the human body when it is suffering from conditions like birth defects.

They are trying to study how the stem cells transform or separate into a wide range of specialized cells so that they can be utilize them in the treatment of certain diseases and conditions.

Stem cells have a huge potential in the testing of drugs as they are relatively safe and dont put anyone in harms way, drugs are now first tested on stem cells and then on animals and humans if the test on stem cells goes well.

- Advertisement -

Excerpt from:
4 Benefits of Stem Cell Therapy that you will Love to Discuss in Future - The Crypto Coin Discovery

Bone Marrow Stem Cells Comments Off on 4 Benefits of Stem Cell Therapy that you will Love to Discuss in Future – The Crypto Coin Discovery | April 22nd, 2020

SILVER SPRING, Md., April 22, 2020 /PRNewswire/ --Today, the U.S. Food and Drug Administration granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.

"Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of Trodelvy today represents a new targeted therapy for patients living with this aggressive malignancy," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research. "There is intense interest in finding new medications to help treat metastatic triple-negative breast cancer. Today's approval provides patients who've already tried two prior therapies with a new option."

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, meaning that the drug targets the Trop-2 receptor that helps the cancer grow, divide and spread, and is linked to topoisomerase inhibitor, which is a chemical compound that is toxic to cancer cells. Approximately two of every 10 breast cancer diagnoses worldwide are triple-negative. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2(HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.

"As part of FDA's ongoing and aggressive commitment to address the novel coronavirus pandemic, we continue to keep a strong focus on patients with cancer who constitute a vulnerable population at risk of contracting the disease," said Pazdur. "At this critical time, we continue to expedite oncology product development. This application was approved more than a month ahead of the FDA goal date an example of that commitment. Our staff is continuing to meet with drug developers, academic investigators, and patient advocates to push forward the coordinated review of treatments for cancer."

The FDA approved Trodelvy based on the results of a clinical trial of 108 patients with metastatic triple-negative breast cancer who had received at least two prior treatments for metastatic disease. The efficacy of Trodelvy was based on the overall response rate (ORR) which reflects the percentage of patients that had a certain amount of tumor shrinkage. The ORR was 33.3%, with a median duration of response of 7.7 months. Of the patients with a response to Trodelvy, 55.6% maintained their response for 6 or more months and 16.7% maintained their response for 12 or more months.

The prescribing information for Trodelvy includes a Boxed Warning to advise health care professionals and patients about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea. Health care professionals should monitor patient's blood cell counts periodically during treatment with Trodelvy and consider treatment with a type of therapy called granulocyte-colony stimulating factor (G-CSF), which stimulates the bone marrow to produce white blood cells called granulocytes and stem cells and releases them into the bloodstream, to help prevent infection, and should initiate anti-infective treatment in patients with febrile neutropenia (development of fever when white blood cell are abnormally low).

Additionally, health care professionals should monitor patients with diarrhea and give fluid, electrolytes, and supportive care medications, as needed. Trodelvy may need to be withheld, dose reduced or permanently discontinued for neutropenia or diarrhea. Trodelvy can cause hypersensitivy reactions including severe anaphylactic (allergic) reactions. Patients should be monitored for infusion-related reactions and health care professionals should discontinue Trodelvy if severe or life-threatening reactions occur. If patients experience nausea or vomiting while taking Trodelvy, health care professionals should use antiemetic preventive treatment, to prevent nausea and vomitting. Patients with reduced uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) activity are at increased risk for neutropenia following initiation of Trodelvy treatment.

The most common side effects for patients taking Trodelvy were nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain.

Women who are pregnant should not take Trodelvy because it may cause harm to a developing fetus or newborn baby. The FDA advises health care professionals to inform females of reproductive age to use effective contraception during treatment with Trodelvy and for 6 months after the last dose. Male patients with female partners of reproductive potential should also use effective contraception during treatment with Trodelvy and for three months after the last dose.

Trodelvy was granted accelerated approval, which enables the FDA to approve drugs for serious conditions to fill an unmet medical need based on a result that is reasonably likely to predict a clinical benefit to patients. Further clinical trials are required to verify and describe Trodelvy's clinical benefit.

The FDA granted this application Priority Review andBreakthrough Therapydesignation, which expedites the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. Trodelvy was also granted Fast Trackdesignation, which expedites the review of drugs to treat serious conditions and fill an unmet medical need.

The FDA granted approval of Trodelvy to Immunomedics, Inc.

Additional Resources:

Media Contact:Nathan Arnold, 301-796-6248Consumer Inquiries: Emailor 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Read this article:
FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments - Herald-Mail Media

Bone Marrow Stem Cells Comments Off on FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments – Herald-Mail Media | April 22nd, 2020

A New Syndicate Global Cell Transplant Market Study is added in HTF MI database compiled covering key business segments and wider geographical scope to get deep dive analysed market data. The study brings a perfect bridging between qualitative and statistical data ofCell Transplant market. The study provides historical data (i.e. Consumption** & Value) from 2014 to 2019 and forecasted till 2026*. Some are the key & emerging players that are part of coverage and have being profiled are Regen Biopharma, Global Cord Blood Corporation, CBR Systems, Escape Therapeutics, Cryo-Save, Lonza Group, Pluristem Therapeutics & Stemedica Cell Technology.

Know how you are perceived in comparison to your competitors like Regen Biopharma, Global Cord Blood Corporation, CBR Systems, Escape Therapeutics, Cryo-Save, Lonza Group, Pluristem Therapeutics & Stemedica Cell Technology; Get an accurate view of your business in Global Cell Transplant Marketplace.

Click to getGlobal Cell Transplant Market Research Sample PDF Copy Instantly

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview

Key Highlights that HTF MI is bringing with this Study Revenue splits by most promising business segments. [By Type (, Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT) & Cord Blood Transplant (CBT)), By Application (Hospitals, Clinics & Others) and any other business Segment if applicable within scope of report] Gap Analysis by Region. Country Level Break-up to dig out Trends and emerging opportunity available in area of your business interest. % Market Share & Sales Revenue by Key Players & Local Regional Players . Dedicated Section on Market Entropy to gain insights on Players aggressive Strategies to built market [Merger & Acquisition / Recent Funding & Investment and Key Developments] Patent Analysis** No of patents / Trademark approval filed & received in recent years. Competitive Landscape: Listed Players Company profile with SWOT, In-depth Overview, Product/Services Specification, Headquarter, Subsidiaries, Downstream Buyers and Upstream Suppliers.

Check Exclusive Discount Offers Available On this Report @https://www.htfmarketreport.com/request-discount/1763360-global-cell-transplant-market

Competitive Landscape:

Mergers & Acquisitions, Agreements & Collaborations, New Product Launches, Business overview & detailed matrix of Product for each player listed in the study. Players exclusively profiled are Regen Biopharma, Global Cord Blood Corporation, CBR Systems, Escape Therapeutics, Cryo-Save, Lonza Group, Pluristem Therapeutics & Stemedica Cell Technology

Most frequently asked question:Why i cant See My company Profiled in the Study?Yes, It might be a possibility that Company you are looking for is not listed, however study is based on vast coverage of players operating inbut due to limited scope and pricing constraints we can only list few random companies keeping a mix of leaders and emerging players. Do contact us if you wish to see any specific company of your interest in the survey. Currently list of companies available in the study are Regen Biopharma, Global Cord Blood Corporation, CBR Systems, Escape Therapeutics, Cryo-Save, Lonza Group, Pluristem Therapeutics & Stemedica Cell Technology

Segment & Regional Analysis: What Market breakdown Would be Covered by geographies, Type & Application/End-users Cell Transplant Market Revenue & Growth Rate by Type [, Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT) & Cord Blood Transplant (CBT)] (Historical & Forecast) Global Cell Transplant Market Revenue & Growth Rate by Application [Hospitals, Clinics & Others] (Historical & Forecast) Cell Transplant Market Revenue & Growth Rate by Each Region Specified (Historical & Forecast) Cell Transplant Market Volume & Growth Rate by Each Region Specified, Application & Type (Historical & Forecast) Cell Transplant Market Revenue, Volume & Y-O-Y Growth Rate by Players (Base Year)

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/1763360-global-cell-transplant-market

To comprehend Global Cell Transplant market dynamics in the world mainly, the worldwide Cell Transplant market is analyzed across major global regions. HTF also provides customized regional and country-level reports

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, Colombia and Brazil. Middle East & Africa: Saudi Arabia, United Arab Emirates, Israel, Turkey, Egypt, Tunisia and South Africa. Europe: United Kingdom, France, Poland, Italy, Germany, Spain, NORDIC {Sweden, Norway, Finland, Denmark etc}, BENELUX {Belgium, The Netherlands, Luxembourg },and Russia. Asia-Pacific: SAARC Nations, China, Japan, South Korea, Southeast Asia, New Zealand & Australia.

Actual Numbers & In-Depth Analysis with emerging trends of Cell Transplant Market Size Estimation Available in Full Copy of Report.

Buy Full Copy Global Cell Transplant Report 2026 @https://www.htfmarketreport.com/buy-now?format=1&report=1763360

Thanks for reading this article, you can also get individual chapter or section or regional study by limiting the scope to just G7 or G20 or European Union Countries, Eastern Europe, East Asia or Southeast Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter

Read the original:
Cell Transplant Market to Witness Huge Growth by 2025 | CBR Systems, Escape Therapeutics, Cryo-Save - Research Columnist

Bone Marrow Stem Cells Comments Off on Cell Transplant Market to Witness Huge Growth by 2025 | CBR Systems, Escape Therapeutics, Cryo-Save – Research Columnist | April 22nd, 2020

I dont know why people pay attention only to vaccines and treatments against the new coronavirus. Stem cell therapies are more useful to treat Covid-19.

So claimed Lee Hee-young, president of the Korean Association of Stemcell Therapy, at a news conference in Seoul, Monday. He called for active use of stem cell therapies to treat Covid-19 patients.

Several studies have proved the effects of autologous stem cells in treating acute respiratory distress syndrome (ARDS), which is the leading cause of death in Covid-19 patients, Lee said. The concept of stem cell therapy is the same as that of blood transfusion or bone marrow transplantation. Decades of cell therapies have proved that stem cell therapy is safe.

While the development of a treatment or a vaccine against Covid-19 takes a long time and it may not be able to treat patients immediately because of virus mutation possibilities, stem cell therapies can restore damaged lungs directly, Lee claimed.

It is more important to restore damaged lungs than to fight the virus. Stem cell therapy restores the lungs, giving patients time to beat the virus, he went on to say. However, people are paying attention to vaccine or treatment candidates only. This is why I am holding a news conference.

Lee pointed out that the local environment makes it difficult to use stem cell therapies. Thus, the government should ease regulations on the management and use of cell culture facilities so that doctors can perform stem cell therapies with simple cell culture, he said.

As long as physicians have a positive pressure facility and a culture kit, they can separate and culture cells with simple training, he said. If the authorities allow doctors to perform stem cell therapies with a disposable mobile culture autonomously, the cost of stem cell therapies will go down significantly.

Lee added that he asked related officials to include such rules in the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals, which is to take effect in the second half of the year.

same@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

More:
'Stem cell therapy more effective on Covid-19' - Korea Biomedical Review - Korea Biomedical Review

Bone Marrow Stem Cells Comments Off on ‘Stem cell therapy more effective on Covid-19’ – Korea Biomedical Review – Korea Biomedical Review | April 21st, 2020

The first COVID-19 patient in Texas has been enrolled in a stem cell therapy clinical trial designed to combat acute respiratory distress syndrome. (Courtesy Pexels)

The patient received the stem cell procedure April 16 at Memorial Hermann-Texas Medical Center, according to a news release from UTHealth. The patient joins 120 total patients as part of the study, in which participants are randomized to receive either allogeneic, bone marrow-derived mesenchymal stromal cells or a placebo.

Patients with ARDS from COVID-19 have a mortality rate up to 60%, said Dr. Bela Patel, co-principal investigator and director of the Division of Critical Care at McGovern Medical School. Since stem cell therapy may modulate the hyperinflammatory response to SARS-CoV-2, which causes COVID-19, this important study represents a promising potential therapy to improving outcomes in ARDS patients including those with COVID-19 ARDS.

ARDS occurs when the lungs cannot supply the oxygen needed for organs throughout the body, caused by fluid building up in the lungs, according to the news release. Patients with COVID-19 who have developed ARDS need to be placed on a ventilator.

Preclinical trials have shown that hMSCs can help regulate the immune response, which lowers inflammation and reduces the severity of organ injury.

For the UTHealth arm of the study, the hMSCs are being processed at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory at McGovern Medical School.

See the article here:
First COVID-19 patient in Texas enrolled in UTHealth stem cell therapy study at Memorial Hermann - Community Impact Newspaper

Bone Marrow Stem Cells Comments Off on First COVID-19 patient in Texas enrolled in UTHealth stem cell therapy study at Memorial Hermann – Community Impact Newspaper | April 21st, 2020

The word steroids are always accompanied by negative comments and inquisitive looks. People have been wary because of its involvement in many controversies and issues throughout the years; and almost always, it involves the sports industry.

As we enter the 21st century, the abuse of anabolic steroids not only escalated, it also became prevalent outside the sports profession. It spread from bodybuilders and fitness instructors to image-conscious teenagers (read more). The youngest to be apprehended was a bunch of 8th graders, ages 15 to 17.

Many are familiar with its potential for misuse, but most are unaware of its medical use in treating several conditions. Anabolic steroids have been the savior of many patients. It helped relieve the symptoms of chronic diseases such as AIDS, myelofibrosis, and lupus. It aided patients suffering from muscle wasting like those undergoing chemotherapy and dialysis.

The appearance and performance-enhancing drug (APED) has many forms and derivatives. One of them is called oxymetholone.

What is oxymetholone?

Oxymetholone is an alkylated synthetic derivative of testosterone. It is one of the few steroids that earned the FDAs approval to be labeled as a prescribed drug, instead of a controlled substance. It is primarily used to treat muscle wasting and several kinds of anemia such as chemo-induced and aplastic anemia.

Like most steroids, oxymetholone has an anabolic-androgenic effect on the human body. The drug is available in the market with the trade names Anadrol 50 and Anapolon. You can only buy Anadrol by getting a medical prescription from your doctor or pharmacist.

How does it work?

Oxymetholones mechanism of action is unlike most anabolic steroids. Once orally ingested, it activates the androgen receptor-mediated signaling in our brain. This binding will start the stimulation of red blood cell production and protein synthesis. This will then promote hemoglobin production and formation of other blood cells. It will also increase the bodys bone density.

Oxymetholone does not bind well to the muscle cells receptor sites. This explains why muscle building and enhancement is only a secondary effect of the drug. But it still brings out the synthetic hormones androgenic effects like increased libido, muscle mass, hirsutism, and voice maturation.

What are its medical uses?

Before the discovery of immunosuppressive drugs, oxymetholone has been at the frontline of managing several chronic anemia cases. Some of its therapeutic benefits are as follows:

Aplastic anemia is a rare and chronic blood disorder that occurs due to stem cell damage inside the bone marrow. This prevents your bone marrow from producing the normal amount of blood cells to sustain your bodys needs. It is characterized as an autoimmune disorder, which means that your own body is producing antibodies to attack and destroy your own bone marrow.

Without treatment, patients will suffer from developing arrhythmia and eventually die from heart failure. Treatments that exist only suppresses the immune system to prevent further production of antibodies. Blood transfusion and the use of oxymetholone are also used to manage aplastic anemia.

The anabolic drug improved the patients hematopoietic development. It increases their RBC production as well as the number of reticulocytes inside the bone marrow.

Another case of blood disorder is the antithrombin deficiency. It is characterized by the production of abnormal blood clots, specifically in the deep veins of the legs.

Clotting should only happen if there is an injury or trauma in the blood vessels. Clots form a stopper-like device inside our body to prevent blood from exiting its vessels. The protein called anti-thrombin prevents our body from forming unnecessary and excessive clots during an injury.

Without it or at low levels, our body would not have a stop signal during clot formation. Thus, creating excessive clots throughout the body that can block the normal blood circulation.

Oxymetholone, in combination with warfarin, is used as a thrombolytic therapy for patients with ATIII deficiency. It augments the bodys fibrinolytic activity and anticoagulant properties.

Hereditary angioedema is a genetic disease characterized by severe swelling in the face, limbs, gastrointestinal tract, and airways. It is a fatal disease due to its common symptom of laryngeal edema. This edema involves the formation of airway and intestinal obstruction that disrupts the normal air delivery to the lungs.

Angioedema is caused by C1 inhibitor deficiency. This protein is found and produced in the bloods plasma or serum. With the use of oxymetholone therapy, a significant increase in the plasma levels of C1 inhibitors is observed. It also improves the level of C4 protein and prevents it from dropping to below normal levels.

The drug is administered to patients in an alternate-day manner. Managing the drug administration prevents side effects like mild virilization and insomnia from occurring.

Chronic weight loss is prevalent in patients undergoing antiretroviral therapy. It can be the medications side effect or from different metabolism alterations. The involuntary loss of weight makes HIV-infected individuals susceptible to opportunistic infections.

To combat this, doctors administered oxymetholone with the antagonist ketotifen to promote weight gain. However, oxymetholone therapy alone showed a much higher increase in the restoration of fat-free muscle mass. Improvements are faster together with proper food intake and mild exercise.

What are its side effects?

Like all medications, the long-term use and abuse of oxymetholone have severe consequences to the body. Fatal ones include the formation of blood-filled cysts or tumors in the liver and spleen. Some long-term aid effects also include:

Allergic reactions such as hives, face swelling, and breathing difficulties may occur during short-term use.

Individuals diagnosed with diabetes, kidney and liver disease, breast and prostate cancer, and cardiovascular diseases may suffer severe conditions if administered with anabolic steroids.

According to the law, oxymetholone must be used under strict medical supervision. Prescription labels should be followed, and dosages may only be changed by your doctor. Skipping or abruptly stopping the medication without consent is highly prohibited.

Read this article:
Where To Find Anadrol 50 (Oxymetholone) for Sale - FeastMagazine

Bone Marrow Stem Cells Comments Off on Where To Find Anadrol 50 (Oxymetholone) for Sale – FeastMagazine | April 21st, 2020

Mount Sinai Health System announced that they will be using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy, in patients with coronavirus disease 2019 (COVID-19).

Additionally, Mount Sinai indicated that they will play a central role in a clinical trial for patients with severe acute respiratory distress syndrome, which affects individuals with severe cases of COVID-19.

Remestemcel-L has previously been tested in patients who have had a bone marrow transplant, who can experience an overactive immune response similar to that observed in severe cases of COVID-19.

Mount Sinai began administering remestemcel-L to patients in late March under the FDAs compassionate use program. The therapy was given to 10 patients with moderate to severe cases of COVID-19-related acute respiratory distress syndrome (ARDS), most of whom were on ventilators, and the doctors saw encouraging results.

We are encouraged by what we have seen so far and look forward to participating in the randomized controlled trial starting soon that would better indicate whether this is an effective therapy for patients in severe respiratory distress from COVID-19, Keren Osman, MD, medical director of the Cellular Therapy Service in the Bone Marrow and Stem Cell Transplantation Program at The Tisch Cancer Institute at Mount Sinai and associate professor of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, said in a press release.

The randomized clinical trial evaluating the therapeutic benefit and safety of remestemcel-L will be conducted at Mount Sinai, which will serve as the clinical and data coordinating center. The stem cell therapy will be evaluated in 240 patients with COVID-19-related ARDS in the US and Canada. Moreover, the trial will be conducted as a public-private partnership between the Cardiothoracic Surgical Trials Network.

The coronavirus pandemic has caused exponential increases of people suffering with acute respiratory distress syndrome, requiring intubation and mechanical ventilation with many dying, Annetine Gelijns, PhD, the Edmond A. Guggenheim Professor of Health Policy at the Icahn School of Medicine at Mount Sinai, said in a press release. We have designed a clinical trial that will expeditiously determine whether the stem cell therapy will offer a life-saving therapy for a group of patients with a dismal prognosis.

Remestemcel-L consists of mesenchymal stem cells. The therapy was previously assessed in a phase III trial in children who had graft-versus-host disease (GVHD), which can occur after bone marrow transplants. Further, the inflammation that occurs in GVHD is the result of a cytokine storm. A similar cytokine storm has been found to take place in patients with COVID-19 who develop acute respiratory distress syndrome.

These stem cells have shown excellent response rates in severe graft-versus-host disease in children, John Levine, MD, professor of Hematology, Medical Oncology, and Pediatrics at the Icahn School of Medicine at Mount Sinai, who is also the co-director of the Mount Sinai Acute GVHD International Consortium (MAGIC), said in a press release. Mesenchymal stem cells have a natural property that dampens excessive immune responses.

Some institutions have also begun testing anti-IL-6 agents, such as tocilizumab (Actemra), for the treatment of cytokine release syndrome in patients with COVID-19 who develop acute respiratory distress syndrome.

Reference:

Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients [news release]. New York, NY. Published April 9, 2020. newswise.com/coronavirus/mount-sinai-leading-the-way-in-innovative-stem-cell-therapy-for-covid-19-patients/?article_id=729684&sc=dwhr&xy=10019792. Accessed April 15, 2020.

See the article here:
Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19 - Cancer Network

Bone Marrow Stem Cells Comments Off on Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19 – Cancer Network | April 20th, 2020

PHOENIX, April 20, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells. The patent covers use of mesenchymal stem cells, a class of adult stem cells, for use in treatment of ovarian failure and ovarian aging.

This patent is a substantial milestone for the Company given that subsequent to filing, several academic groups published the ability of mesenchymal stem cells to treat ovarian failure in animal models.1,2

"We are pleased by the issuance of these broad claims, which not only cover a clinically-used family of stem cells, but also the cells which produce blood vessels, called Endothelial Progenitor Cells (EPC)," said Thomas Ichim, Ph.Dco-inventor and Chief Scientific Officer. "Mesenchymal stem cells isolated from a wide variety of tissues such as bone marrow, adipose tissue, umbilical cord and even teeth, have been used in clinical trials for other diseases. Given the availability, practicality and strong safety record of this class of cells, we are in a position to choose from many developmental possibilities."

Issuance adds to the existing portfolio of clinically translated adult stem cell intellectual property which include issued patents for the treatment of erectile dysfunction using bone marrow stem cells and covering treatment of disc degeneration by similar means.

According to the American Pregnancy Association:3

"Approximately1 in every 1000women between the ages of 15-29 and 1 in every 100 women between the ages of 30-39 are affected byPremature Ovarian Failure (POF)also called premature menopause. A woman can beaffected by POF at any age or time in her life. It can happen beforeor after she has had children or while she is still planning her family.

Premature ovarian failure is the loss of ovarian function in women under the age of 40. Women with POF do not ovulate (release an egg) each month. This loss of function can be due to a less than normal amount of follicles or dysfunction in the ovaries."

"The mission of Creative Medical Technology Holdings has always been to concurrently create a strong intellectual property base which is derived from ongoing basic research, while advancing our clinicallyused products such as CaverStem, StemSpine and FemCelz," said Timothy Warbington, President and CEO of the Company. "The issuance of such broad claims allows us not only to develop, but to potentially out license this landmark patent."

A "Quayle Action" is issued when there are minor issues to be resolved in a patent application that is otherwise in condition forallowance. Prosecution on the merits is closed, meaning that substantive examination has concluded.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit http://www.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at http://www.sec.gov.

Creativemedicaltechnology.comCaverstem.comFemcelz.comStemSpine.com

1Mohamed et al. Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure.Reprod Sci. 2018 Jan;25(1):51-63.2Badawy et al. Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model. Int J Womens Health. 2017 Jun 15;9:441-4473https://americanpregnancy.org/womens-health/premature-ovarian-failure/

More here:
Creative Medical Technology Holdings is Granted Patent on Mesenchymal Stem Cells for Female Infertility Pending Quayle Action - Apache Junction News

Bone Marrow Stem Cells Comments Off on Creative Medical Technology Holdings is Granted Patent on Mesenchymal Stem Cells for Female Infertility Pending Quayle Action – Apache Junction News | April 20th, 2020